324 related articles for article (PubMed ID: 37119122)
1. Advances in CRISPR/Cas9 Genome Editing for the Treatment of Muscular Dystrophies.
Fatehi S; Marks RM; Rok MJ; Perillat L; Ivakine EA; Cohn RD
Hum Gene Ther; 2023 May; 34(9-10):388-403. PubMed ID: 37119122
[TBL] [Abstract][Full Text] [Related]
2. In Vivo Genome Editing Restores Dystrophin Expression and Cardiac Function in Dystrophic Mice.
El Refaey M; Xu L; Gao Y; Canan BD; Adesanya TMA; Warner SC; Akagi K; Symer DE; Mohler PJ; Ma J; Janssen PML; Han R
Circ Res; 2017 Sep; 121(8):923-929. PubMed ID: 28790199
[TBL] [Abstract][Full Text] [Related]
3. CRISPR-Based Gene Therapies: From Preclinical to Clinical Treatments.
Laurent M; Geoffroy M; Pavani G; Guiraud S
Cells; 2024 May; 13(10):. PubMed ID: 38786024
[TBL] [Abstract][Full Text] [Related]
4. Muscle-specific CRISPR/Cas9 dystrophin gene editing ameliorates pathophysiology in a mouse model for Duchenne muscular dystrophy.
Bengtsson NE; Hall JK; Odom GL; Phelps MP; Andrus CR; Hawkins RD; Hauschka SD; Chamberlain JR; Chamberlain JS
Nat Commun; 2017 Feb; 8():14454. PubMed ID: 28195574
[TBL] [Abstract][Full Text] [Related]
5. Genome Editing of Monogenic Neuromuscular Diseases: A Systematic Review.
Long C; Amoasii L; Bassel-Duby R; Olson EN
JAMA Neurol; 2016 Nov; 73(11):1349-1355. PubMed ID: 27668807
[TBL] [Abstract][Full Text] [Related]
6. CRISPR-Cas9 Gene Therapy for Duchenne Muscular Dystrophy.
Happi Mbakam C; Lamothe G; Tremblay G; Tremblay JP
Neurotherapeutics; 2022 Apr; 19(3):931-941. PubMed ID: 35165856
[TBL] [Abstract][Full Text] [Related]
7. Restoration of dystrophin expression and correction of Duchenne muscular dystrophy by genome editing.
Aslesh T; Erkut E; Yokota T
Expert Opin Biol Ther; 2021 Aug; 21(8):1049-1061. PubMed ID: 33401973
[No Abstract] [Full Text] [Related]
8. CRISPR technologies for the treatment of Duchenne muscular dystrophy.
Choi E; Koo T
Mol Ther; 2021 Nov; 29(11):3179-3191. PubMed ID: 33823301
[TBL] [Abstract][Full Text] [Related]
9. In vivo genome editing in mouse restores dystrophin expression in Duchenne muscular dystrophy patient muscle fibers.
Chen M; Shi H; Gou S; Wang X; Li L; Jin Q; Wu H; Zhang H; Li Y; Wang L; Li H; Lin J; Guo W; Jiang Z; Yang X; Xu A; Zhu Y; Zhang C; Lai L; Li X
Genome Med; 2021 Apr; 13(1):57. PubMed ID: 33845891
[TBL] [Abstract][Full Text] [Related]
10. In vivo genome editing improves muscle function in a mouse model of Duchenne muscular dystrophy.
Nelson CE; Hakim CH; Ousterout DG; Thakore PI; Moreb EA; Castellanos Rivera RM; Madhavan S; Pan X; Ran FA; Yan WX; Asokan A; Zhang F; Duan D; Gersbach CA
Science; 2016 Jan; 351(6271):403-7. PubMed ID: 26721684
[TBL] [Abstract][Full Text] [Related]
11. CRISPR/Cas correction of muscular dystrophies.
Zhang Y; Nishiyama T; Olson EN; Bassel-Duby R
Exp Cell Res; 2021 Nov; 408(1):112844. PubMed ID: 34571006
[TBL] [Abstract][Full Text] [Related]
12. CRISPR-Editing Therapy for Duchenne Muscular Dystrophy.
Chemello F; Olson EN; Bassel-Duby R
Hum Gene Ther; 2023 May; 34(9-10):379-387. PubMed ID: 37060194
[TBL] [Abstract][Full Text] [Related]
13. The gRNA Vector Level Determines the Outcome of Systemic AAV CRISPR Therapy for Duchenne Muscular Dystrophy.
Wasala NB; Million ED; Watkins TB; Wasala LP; Han J; Yue Y; Lu B; Chen SJ; Hakim CH; Duan D
Hum Gene Ther; 2022 May; 33(9-10):518-528. PubMed ID: 35350865
[TBL] [Abstract][Full Text] [Related]
14. Long-term evaluation of AAV-CRISPR genome editing for Duchenne muscular dystrophy.
Nelson CE; Wu Y; Gemberling MP; Oliver ML; Waller MA; Bohning JD; Robinson-Hamm JN; Bulaklak K; Castellanos Rivera RM; Collier JH; Asokan A; Gersbach CA
Nat Med; 2019 Mar; 25(3):427-432. PubMed ID: 30778238
[TBL] [Abstract][Full Text] [Related]
15. Prevention of muscular dystrophy in mice by CRISPR/Cas9-mediated editing of germline DNA.
Long C; McAnally JR; Shelton JM; Mireault AA; Bassel-Duby R; Olson EN
Science; 2014 Sep; 345(6201):1184-1188. PubMed ID: 25123483
[TBL] [Abstract][Full Text] [Related]
16. Gene editing of Duchenne muscular dystrophy using biomineralization-based spCas9 variant nanoparticles.
Li S; Du M; Deng J; Deng G; Li J; Song Z; Han H
Acta Biomater; 2022 Dec; 154():597-607. PubMed ID: 36243370
[TBL] [Abstract][Full Text] [Related]
17. Correction of Three Prominent Mutations in Mouse and Human Models of Duchenne Muscular Dystrophy by Single-Cut Genome Editing.
Min YL; Chemello F; Li H; Rodriguez-Caycedo C; Sanchez-Ortiz E; Mireault AA; McAnally JR; Shelton JM; Zhang Y; Bassel-Duby R; Olson EN
Mol Ther; 2020 Sep; 28(9):2044-2055. PubMed ID: 32892813
[TBL] [Abstract][Full Text] [Related]
18. Enhanced CRISPR-Cas9 correction of Duchenne muscular dystrophy in mice by a self-complementary AAV delivery system.
Zhang Y; Li H; Min YL; Sanchez-Ortiz E; Huang J; Mireault AA; Shelton JM; Kim J; Mammen PPA; Bassel-Duby R; Olson EN
Sci Adv; 2020 Feb; 6(8):eaay6812. PubMed ID: 32128412
[TBL] [Abstract][Full Text] [Related]
19. Molecular correction of Duchenne muscular dystrophy by splice modulation and gene editing.
Hanson B; Wood MJA; Roberts TC
RNA Biol; 2021 Jul; 18(7):1048-1062. PubMed ID: 33472516
[TBL] [Abstract][Full Text] [Related]
20. Scalpel or Straitjacket: CRISPR/Cas9 Approaches for Muscular Dystrophies.
Himeda CL; Jones TI; Jones PL
Trends Pharmacol Sci; 2016 Apr; 37(4):249-251. PubMed ID: 26917062
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
